Generic PIVMECILLINAM HYDROCHLORIDE INN equivalents, drug patent expiration information and freedom to operate

Sponsor	Phase
The Swedish Research Council	PHASE4
Uppsala University	PHASE4
Uppsala Clinical Research Center, Sweden	PHASE4

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alembic Therap	PIVYA	pivmecillinam hydrochloride	TABLET;ORAL	216483-001	Apr 24, 2024		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: September 13, 2026

Pivmecillinam hydrochloride has a two-stage commercial profile. In Europe, it is an established oral antibiotic used mainly for uncomplicated urinary tract infections. In the United States, its commercial market began with FDA approval of Pivya in April 2024. The U.S. opportunity is strategically important because pivmecillinam became the first FDA-approved oral antibiotic specifically positioned for uncomplicated urinary tract infections caused by susceptible bacteria, but early revenue remains dependent on formulary access, primary-care prescribing, antibiotic stewardship, and payer coverage.

Public filings do not provide a reliable standalone revenue history or consensus forecast for pivmecillinam hydrochloride. The most defensible financial assessment is therefore based on regulatory timing, addressable patient volume, pricing potential, generic-entry timing, and the competitive position against existing oral UTI antibiotics.

What is pivmecillinam hydrochloride and how is it used?

Pivmecillinam hydrochloride is the orally administered hydrochloride salt of pivmecillinam, a prodrug converted to mecillinam after absorption. Mecillinam has preferential activity against Gram-negative organisms, including many strains of Escherichia coli, the dominant cause of uncomplicated cystitis.

The FDA-approved product is Pivya, supplied as 185 mg tablets. The approved indication is treatment of uncomplicated urinary tract infections caused by susceptible microorganisms in adult women and includes Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus. The labeled regimen is one tablet three times daily for five days, taken with food. The product is not approved for pyelonephritis or systemic infection (FDA, 2024a).

Pivmecillinam has been used for decades in Denmark, Sweden, Norway, the United Kingdom, and other European markets. Its European commercial role is broader than its initial U.S. role because it is incorporated into national treatment practices and benefits from long clinical experience.

What was the FDA approval date for Pivya?

The FDA approved Pivya on April 24, 2024, through the traditional new drug application pathway. Utility Therapeutics Ltd. is the commercial sponsor in the United States. The approval followed a priority-review process and included a Qualified Infectious Disease Product designation under the Generating Antibiotic Incentives Now Act framework (FDA, 2024b).

Milestone	Date or status
European clinical use	Several decades before U.S. approval
U.S. NDA approval	April 24, 2024
U.S. product	Pivya
Sponsor	Utility Therapeutics Ltd.
Dosage form	185 mg oral tablet
U.S. indication	Uncomplicated UTI in adult women
Treatment duration	Five days
FDA regulatory designation	Qualified Infectious Disease Product
Initial U.S. commercial market	2024 onward

The U.S. approval creates a new branded market rather than converting an existing FDA-approved generic market. That gives the sponsor an opportunity to establish clinical use, but it also requires physicians and payers to change prescribing behavior in a category with inexpensive generic alternatives.

How large is the pivmecillinam hydrochloride market?

The global market is divided between a mature European market and an emerging U.S. market.

Europe is the established revenue base. Pivmecillinam is prescribed primarily for lower urinary tract infections and is commonly available through generic or multisource products. Pricing is generally constrained by national reimbursement systems, generic competition, and antibiotic budget controls. European sales are therefore likely to be volume-driven rather than premium-price-driven.

The U.S. market has greater pricing potential but higher commercial execution risk. The relevant patient population is adult women with uncomplicated cystitis who would otherwise receive nitrofurantoin, trimethoprim-sulfamethoxazole, fosfomycin, or an oral beta-lactam. The Centers for Disease Control and Prevention estimates that urinary tract infections account for millions of outpatient visits annually, while a substantial portion of antibiotic prescribing occurs in outpatient settings (CDC, 2022).

Pivya’s addressable market is narrower than the total UTI market because:

The label is limited to uncomplicated UTI.
It is not approved for pyelonephritis.
It is not indicated for complicated UTI.
It is limited to adult women.
Susceptibility testing and local resistance patterns influence use.
Payer formularies may place the product behind lower-cost generic antibiotics.

The most likely commercial model is a specialty branded antibiotic with moderate unit volume, premium pricing relative to generic alternatives, and gradual adoption through urgent-care clinics, primary-care practices, gynecology, telehealth, and hospital discharge protocols.

How does pivmecillinam compare with competing UTI antibiotics?

Pivmecillinam competes against established oral therapies rather than other newly launched branded products.

Drug	Typical role in uncomplicated cystitis	Commercial position	Key limitation
Nitrofurantoin	Common first-line treatment	Low-cost generic	Limited utility in some renal-function settings and unsuitable for pyelonephritis
Trimethoprim-sulfamethoxazole	First-line option where susceptibility is adequate	Low-cost generic	Resistance and allergy concerns
Fosfomycin	Single-dose oral treatment	Generic or low-cost branded supply	Variable susceptibility and single-dose efficacy concerns
Oral beta-lactams	Alternative treatment	Generic	Often less preferred because of efficacy or resistance considerations
Pivmecillinam	Established European option; new U.S. option	Branded U.S. product, generic European products	New U.S. prescribing history and likely price premium

The strongest clinical-commercial argument for pivmecillinam is preservation of treatment options in the face of resistance to commonly used agents. The strongest commercial obstacle is that physicians can already choose several generic antibiotics with established reimbursement pathways.

The Infectious Diseases Society of America has identified pivmecillinam as an important treatment option in international guidance, particularly where local availability and susceptibility support use (Gupta et al., 2011). U.S. adoption will depend on updated clinical guidance, infectious-disease stewardship policies, and payer treatment algorithms.

When does pivmecillinam lose U.S. exclusivity?

Pivmecillinam’s U.S. exclusivity is more important than any legacy European patent because the active ingredient has been used internationally for decades.

The FDA approval of Pivya may qualify for five years of new chemical entity exclusivity if the agency determines that pivmecillinam is a new active moiety for U.S. regulatory purposes. A Qualified Infectious Disease Product designation can add five years to applicable exclusivity periods under the GAIN Act. On that statutory basis, the potential exclusivity period could extend to approximately April 2034, although the precise date depends on the FDA’s Orange Book listing and exclusivity determination (FDA, 2024c).

Protection mechanism	Potential relevance
New chemical entity exclusivity	Potential five-year period from U.S. approval
QIDP exclusivity extension	Potential five-year addition to applicable exclusivity
Formulation patents	Could protect a specific tablet formulation or manufacturing process
Method-of-use patents	Could protect selected treatment methods if listed and enforceable
European legacy patents	Limited direct effect on U.S. entry
Data exclusivity	Relevant to generic and hybrid applications under U.S. law

The practical entry date for a generic depends on the final Orange Book exclusivity record, listed patents, Paragraph IV certifications, litigation, and any settlement. A five-year NCE period would generally prevent an ANDA from being submitted before April 2029. If the full QIDP extension applies, the filing and approval timetable could move materially later.

What patents protect Pivya and pivmecillinam hydrochloride?

The active ingredient does not have the profile of a recently discovered antibiotic. Pivmecillinam and mecillinam have long histories of clinical use outside the United States, which limits the value of broad composition-of-matter protection.

The commercially relevant U.S. estate is more likely to depend on:

Product-specific tablet formulations.
Salt, dosage, or release characteristics.
Manufacturing methods.
Crystalline or solid-state forms.
Treatment methods directed to defined patient groups or susceptible pathogens.
Regulatory exclusivity rather than long-lived molecule patents.

The FDA Orange Book, not the European patent record, is the controlling source for determining whether patents are listed against Pivya. As of the initial U.S. approval period, public information did not establish a broad, long-duration U.S. patent estate comparable to the estates surrounding recently launched specialty antibiotics.

How strong is the pivmecillinam patent estate?

The estate appears commercially moderate rather than exceptionally strong.

Its advantages are regulatory:

Pivya is the first FDA-approved U.S. product.
The product may receive NCE exclusivity.
QIDP status can extend applicable exclusivity.
The sponsor has a first-mover opportunity in U.S. clinical practice.

Its weaknesses are structural:

The molecule is old internationally.
The active ingredient is not protected by a typical late-stage pharmaceutical composition patent.
Several generic antibiotics already compete in the same indication.
A formulation patent would likely protect a narrower product configuration.
Method-of-use patents may face validity and infringement challenges if their scope is narrow.

Are there Paragraph IV challenges or generic launches?

No public U.S. Paragraph IV litigation or settlement involving Pivya was established during the initial post-approval period covered by the available regulatory record.

Generic entry is unlikely to occur immediately because the product first requires an ANDA pathway, a reference-product designation, and resolution of any applicable exclusivity. If Pivya receives five years of NCE protection, the earliest ANDA filing window would generally begin in 2029. A commercial generic launch could occur later, depending on approval timing and litigation.

Three launch scenarios are commercially relevant:

Scenario	Timing	Market effect
Exclusivity-led launch	Around 2029 to 2030	Pivya retains branded pricing while adoption develops
Patent litigation delay	After 2030	Higher cumulative branded revenue and longer payer conversion period
Early settlement or weak patent estate	Before or near exclusivity end	Rapid price erosion and limited long-term branded value

The European market has a different risk profile because pivmecillinam products are already available in generic or multisource forms in several countries.

What is the financial trajectory for pivmecillinam hydrochloride?

The financial trajectory has four stages.

European base business

European revenue is mature and likely stable rather than high-growth. The product benefits from clinical familiarity, but national price controls and generic competition limit margin expansion. Revenue is tied to prescription volume, public-health policies, and resistance-driven prescribing.

U.S. launch investment

The U.S. launch requires spending on market access, medical education, sales infrastructure, distribution, pharmacovigilance, and payer contracting. Early operating expenses may exceed product revenue while prescribers become familiar with pivmecillinam.

U.S. adoption period

The principal revenue inflection point will depend on formulary placement and repeat prescribing. Adoption is likely to be concentrated in settings where clinicians encounter resistant uropathogens, intolerance to first-line therapies, or limited treatment options.

A premium price is possible because Pivya is a branded first-in-class U.S. product. The price ceiling remains constrained by:

Generic nitrofurantoin and trimethoprim-sulfamethoxazole.
Payer step therapy.
Short treatment duration.
Outpatient antibiotic stewardship.
The availability of fosfomycin and oral beta-lactams.

Post-exclusivity erosion

Once an FDA-approved generic enters, pivmecillinam revenue could decline quickly. The product is an oral tablet with no complex delivery system, no biologic manufacturing barrier, and no apparent need for specialized administration. Those factors make generic substitution relatively straightforward if the regulatory and patent barriers expire.

Public disclosures available around the 2024 approval did not establish product-level net sales, EBITDA, or a reliable revenue forecast. The financial value therefore rests more on the duration of U.S. regulatory protection and the sponsor’s ability to secure reimbursement than on an established historical revenue stream.

Does pivmecillinam face biosimilar risk?

No. Pivmecillinam hydrochloride is a small-molecule antibiotic, not a biologic. Biosimilar regulation is irrelevant. The competitive threat is conventional generic substitution through an ANDA or, depending on the product configuration, another FDA-approved small-molecule pathway.

The manufacturing barrier is also relatively limited compared with biologics. The key manufacturing risks are chemical purity, salt formation, tablet stability, dissolution, and consistency of the finished dosage form. Those risks can delay approval but are unlikely to prevent eventual generic competition.

What litigation and settlement risks affect Pivya?

The main potential disputes are likely to involve:

Orange Book patent listing;
Paragraph IV certifications;
Patent validity;
Infringement of formulation or manufacturing claims;
Scope of QIDP and NCE exclusivity;
Labeling carve-outs for any protected method of use.

No publicly disclosed settlement agreement or material U.S. patent litigation was identified in the initial approval period. A future settlement could permit an authorized or independent generic launch before the end of all listed patent terms. Such an agreement would materially affect the sponsor’s revenue curve and valuation.

What is the competitive outlook for pivmecillinam?

Pivmecillinam has a defensible clinical niche but not an uncontested market.

Its strongest commercial assets are U.S. regulatory novelty, European clinical experience, Gram-negative activity, and potential extended exclusivity. Its main constraints are generic competition, the narrow uncomplicated-UTI indication, and the limited ability to justify a large price premium for a five-day oral therapy.

The most likely outcome is a moderate U.S. revenue opportunity rather than a blockbuster market. Upside depends on resistance trends, guideline inclusion, and payer coverage. Downside arises if Pivya is treated as a reserve option or placed behind inexpensive generics.

Key Takeaways

Pivya received FDA approval on April 24, 2024, for uncomplicated UTI in adult women.
Pivmecillinam hydrochloride has a mature European market and a new U.S. branded market.
The U.S. revenue opportunity depends on payer access and clinical adoption more than on unmet demand alone.
Potential NCE and QIDP exclusivity could provide protection into approximately 2034, subject to the FDA’s final regulatory record.
The molecule’s legacy use outside the United States limits the strategic value of broad composition patents.
No public U.S. Paragraph IV litigation or settlement was established during the initial post-approval period.
Biosimilar risk does not apply; conventional generic substitution is the principal long-term threat.
The likely financial profile is gradual U.S. growth followed by sharp erosion after generic entry.

FAQs

Is pivmecillinam hydrochloride available in the United States?

Yes. The FDA-approved U.S. product is Pivya, marketed by Utility Therapeutics for uncomplicated urinary tract infections in adult women.

Is Pivya a generic antibiotic?

No. Pivya is a branded FDA-approved product in the United States. Pivmecillinam products have existed as generic or multisource medicines in several European markets.

Can pivmecillinam be used for kidney infections?

Pivya is not FDA-approved for pyelonephritis. Its U.S. indication is limited to uncomplicated urinary tract infections.

What will determine Pivya’s peak sales?

The main drivers are formulary placement, reimbursement, prescriber adoption, resistance-driven demand, guideline inclusion, and the timing of generic entry.

Is pivmecillinam strategically important for antibiotic resistance?

It can expand oral treatment options for susceptible Gram-negative urinary pathogens, particularly when resistance or intolerance limits the use of commonly prescribed agents. Its commercial impact will depend on stewardship policies and susceptibility testing.

References

Centers for Disease Control and Prevention. (2022). Adult outpatient treatment recommendations: Urinary tract infection. U.S. Department of Health and Human Services.

Food and Drug Administration. (2024a). Pivya (pivmecillinam hydrochloride) prescribing information. U.S. Department of Health and Human Services.

Food and Drug Administration. (2024b, April 24). FDA approves new treatment for uncomplicated urinary tract infections. U.S. Department of Health and Human Services.

Food and Drug Administration. (2024c). Orange Book: Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

Gupta, K., Hooton, T. M., Naber, K. G., Wullt, B., Colgan, R., Miller, L. G., Moran, G. J., Nicolle, L. E., Raz, R., Schaeffer, A. J., & Soper, D. E. (2011). International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women. Clinical Infectious Diseases, 52(5), e103-e120. https://doi.org/10.1093/cid/ciq257

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	8
Patent Applications:	234
DailyMed Link:	PIVMECILLINAM HYDROCHLORIDE at DailyMed

PIVMECILLINAM HYDROCHLORIDE - Generic Drug Details

What are the generic sources for pivmecillinam hydrochloride and what is the scope of freedom to operate?

Summary for PIVMECILLINAM HYDROCHLORIDE

Recent Clinical Trials for PIVMECILLINAM HYDROCHLORIDE

Anatomical Therapeutic Chemical (ATC) Classes for PIVMECILLINAM HYDROCHLORIDE

US Patents and Regulatory Information for PIVMECILLINAM HYDROCHLORIDE

Pivmecillinam Hydrochloride Market Dynamics and Financial Trajectory